中国药物应用与监测
中國藥物應用與鑑測
중국약물응용여감측
CHINESE JOURNAL OF DRUG APPLICATION AND MONITORING
2014年
6期
334-336,337
,共4页
腹腔热灌注%卵巢癌%腹腔积液
腹腔熱灌註%卵巢癌%腹腔積液
복강열관주%란소암%복강적액
Hyperthermic intraperitoneal chemotherapy%Ovarian cancer%Ascites
目的：探讨腹腔热灌注化疗对于卵巢癌恶性腹腔积液的有效性和安全性，为临床治疗提供参考。方法：收集我院2011年6月–2014年7月期间卵巢癌恶性腹腔积液患者，共计49例，分为治疗组（腹腔热灌注顺铂化疗组）25例和对照组（单纯腹腔顺铂化疗组）24例。两组均每周灌注2次，连续治疗3周，评价治疗有效率、生活质量及毒副反应。结果：治疗组治疗有效率及KPS评分改善率分别为84.0%和84.0%，均显著高于对照组（54.2%和45.8%），差异具有统计学意义（P<0.05），且未出现严重毒副反应。结论：腹腔热灌注化疗可显著提高卵巢癌恶性腹腔积液患者近期疗效及生存质量，且耐受性良好。
目的：探討腹腔熱灌註化療對于卵巢癌噁性腹腔積液的有效性和安全性，為臨床治療提供參攷。方法：收集我院2011年6月–2014年7月期間卵巢癌噁性腹腔積液患者，共計49例，分為治療組（腹腔熱灌註順鉑化療組）25例和對照組（單純腹腔順鉑化療組）24例。兩組均每週灌註2次，連續治療3週，評價治療有效率、生活質量及毒副反應。結果：治療組治療有效率及KPS評分改善率分彆為84.0%和84.0%，均顯著高于對照組（54.2%和45.8%），差異具有統計學意義（P<0.05），且未齣現嚴重毒副反應。結論：腹腔熱灌註化療可顯著提高卵巢癌噁性腹腔積液患者近期療效及生存質量，且耐受性良好。
목적：탐토복강열관주화료대우란소암악성복강적액적유효성화안전성，위림상치료제공삼고。방법：수집아원2011년6월–2014년7월기간란소암악성복강적액환자，공계49례，분위치료조（복강열관주순박화료조）25례화대조조（단순복강순박화료조）24례。량조균매주관주2차，련속치료3주，평개치료유효솔、생활질량급독부반응。결과：치료조치료유효솔급KPS평분개선솔분별위84.0%화84.0%，균현저고우대조조（54.2%화45.8%），차이구유통계학의의（P<0.05），차미출현엄중독부반응。결론：복강열관주화료가현저제고란소암악성복강적액환자근기료효급생존질량，차내수성량호。
[ABSTRACT]Objective:To evaluate the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer patients with malignant ascites.Methods: Totally 49 ovarian cancer patients were enrolled in this study from June 2011 to July 2014. A total of 25 cases in treatment group were given with HIPEC combined with cisplatin, and 24 patients were underwent intraperitoneal chemotherapy as a control group. Each patient in treatment group and control group had received six times chemotherapy during three weeks, twice one week. Changes of response rate, quality of life (KPS score) and the side effects were evaluated.Results: The response rate and improvement rate in KPS score were 84.0% and 84.0% respectively in treatment group, which showed higher than those in the control group (54.2% and 45.8%) with statistical signiifcance (P < 0.05). No severe side effect was observed during treatment.Conclusion:HIPEC is a feasible and safe treatment for ovarian carcinoma patients with malignant ascites, which can improve the short-term efifcacy and quality of life.
